MY205849A - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
MY205849A
MY205849A MYPI2019001798A MYPI2019001798A MY205849A MY 205849 A MY205849 A MY 205849A MY PI2019001798 A MYPI2019001798 A MY PI2019001798A MY PI2019001798 A MYPI2019001798 A MY PI2019001798A MY 205849 A MY205849 A MY 205849A
Authority
MY
Malaysia
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
MYPI2019001798A
Inventor
A Demopulos Gregory
John Brunskill Nigel
Dudler Tom
Schwaeble Hans-Wilhelm
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of MY205849A publication Critical patent/MY205849A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation. Fig. 43
MYPI2019001798A 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy MY205849A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (1)

Publication Number Publication Date
MY205849A true MY205849A (en) 2024-11-15

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001798A MY205849A (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (19)

Country Link
EP (1) EP3525798A4 (en)
JP (1) JP6893554B2 (en)
KR (1) KR102348939B1 (en)
CN (2) CN116726163A (en)
AU (1) AU2017342428B2 (en)
BR (1) BR112019007426A2 (en)
CA (2) CA3210384A1 (en)
CL (2) CL2019000909A1 (en)
GE (2) GEP20247587B (en)
IL (1) IL265981B2 (en)
JO (1) JOP20190068B1 (en)
MA (1) MA46541A (en)
MX (1) MX2019004074A (en)
MY (1) MY205849A (en)
PH (1) PH12019500711B1 (en)
SG (1) SG11201902941UA (en)
UA (1) UA126908C2 (en)
WO (1) WO2018071701A1 (en)
ZA (1) ZA201902933B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (en) * 2020-03-19 2020-07-17 长春市儿童医院 Glomerular lobular nephropathy modeling method
CN115215937B (en) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 Anti-human MASP-2 antibody, preparation method and application thereof
PY22106817A (en) 2021-12-10 2023-12-21 Omeros Corp THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE-PROTEASE DOMAIN OF MASP-2 AND THEIR USES
CN116392488B (en) * 2023-05-22 2025-03-28 中南大学湘雅医院 Application of an alkaloid compound in the preparation of a drug for preventing and treating diabetic nephropathy
CN117016486B (en) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 Animal model construction method for IgA nephropathy combined membranous nephropathy
WO2026026712A1 (en) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 Sirna for inhibiting masp2 gene expression, and modifier thereof and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1798769A (en) * 2003-05-12 2006-07-05 内蒂穆恩公司 Antibodies to masp-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107638565B (en) * 2011-04-08 2021-12-21 莱斯特大学 Methods for treating conditions associated with MASP-2 dependent complement activation
MX361175B (en) * 2011-05-04 2018-11-29 Omeros Corp Compositions for inhibiting masp-2 dependent complement acitivation.
AU2014229020B2 (en) * 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
RS61351B1 (en) * 2013-10-17 2021-02-26 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
SG11201805695SA (en) * 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (en) * 2016-08-31 2022-09-15 Omeros Corp High concentration, low viscosity MASP-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number Publication date
AU2017342428A1 (en) 2019-05-23
EP3525798A1 (en) 2019-08-21
JOP20190068A1 (en) 2019-04-01
CA3039927C (en) 2023-10-10
ZA201902933B (en) 2023-05-31
WO2018071701A1 (en) 2018-04-19
KR20190063475A (en) 2019-06-07
IL265981B1 (en) 2025-01-01
GEP20247587B (en) 2024-01-25
UA126908C2 (en) 2023-02-22
GEP20267856B (en) 2026-02-10
JP6893554B2 (en) 2021-06-23
AU2017342428B2 (en) 2021-02-04
PH12019500711A1 (en) 2019-11-18
CN116726163A (en) 2023-09-12
KR102348939B1 (en) 2022-01-12
BR112019007426A2 (en) 2019-07-02
JP2019534271A (en) 2019-11-28
CA3210384A1 (en) 2018-04-19
MX2019004074A (en) 2019-06-10
CL2019000909A1 (en) 2019-06-14
CL2019003485A1 (en) 2020-04-13
NZ753260A (en) 2021-11-26
JOP20190068B1 (en) 2024-12-22
EP3525798A4 (en) 2020-07-08
CN110177557A (en) 2019-08-27
CA3039927A1 (en) 2018-04-19
IL265981A (en) 2019-06-30
IL265981B2 (en) 2025-05-01
PH12019500711B1 (en) 2024-04-17
SG11201902941UA (en) 2019-05-30
MA46541A (en) 2019-08-21

Similar Documents

Publication Publication Date Title
PH12019500711A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MX2021005394A (en) Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
MX2019013072A (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
PH12018501435A1 (en) Methods for inhibiting fibrosis in asubject in need tereof
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
DK3858977T3 (en) STRAIN FOR THE PREVENTION AND TREATMENT OF METABOLISM DISEASES, AND THE USE THEREOF
MD3360559T2 (en) Compositions containing bacterial strains
GB2593097B (en) Cryptographic verification of database transactions
MX2019011423A (en) Methods of treating neurodegenerative diseases.
CY1121806T1 (en) IMIDAZOPYRASINONES AS PDE1 INHIBITORS
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2018008995A (en) Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer.
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2022015248A (en) Methods of treating inflammatory diseases.
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
HK1255056A1 (en) Anti-cd115 antibodies
CR20200027A (en) AGENTS, USES AND METHODS FOR TREATMENT
EA202191471A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
MX378940B (en) NEURODEGENERATIVE DISORDERS.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
CY1122784T1 (en) HALOGONATED QUINOZOLINE-THF-AMINES AS PDE1 INHIBITORS
HK1216754A1 (en) Anti-rankl antibodies and methods of use